biomarkers and risk assessment for chromium(vi) qingshan qu, md (pi) roy shore, phd (co-i) dept. of...
Post on 19-Dec-2015
219 views
TRANSCRIPT
![Page 1: Biomarkers and Risk Assessment for Chromium(VI) Qingshan Qu, MD (PI) Roy Shore, PhD (Co-I) Dept. of Environmental Med. NYU School of Medicine](https://reader036.vdocuments.mx/reader036/viewer/2022081519/56649d2a5503460f949fede7/html5/thumbnails/1.jpg)
Biomarkers and Risk Biomarkers and Risk Assessment for Assessment for Chromium(VI)Chromium(VI)
Qingshan Qu, MD (PI)Qingshan Qu, MD (PI)Roy Shore, PhD (Co-I)Roy Shore, PhD (Co-I)
Dept. of Environmental Med.Dept. of Environmental Med.NYU School of MedicineNYU School of Medicine
![Page 2: Biomarkers and Risk Assessment for Chromium(VI) Qingshan Qu, MD (PI) Roy Shore, PhD (Co-I) Dept. of Environmental Med. NYU School of Medicine](https://reader036.vdocuments.mx/reader036/viewer/2022081519/56649d2a5503460f949fede7/html5/thumbnails/2.jpg)
BackgroundBackground
Toxicity of oxidation states of Toxicity of oxidation states of Chromium (Cr)Chromium (Cr)
– Cr(III) is relatively nontoxic, poorly Cr(III) is relatively nontoxic, poorly absorbed, little crosses cell absorbed, little crosses cell membranes, & may be an essential membranes, & may be an essential elementelement
– Cr(VI) is strong oxidizing agent: Cr(VI) is strong oxidizing agent: toxic and carcinogenic; crosses cell toxic and carcinogenic; crosses cell membranesmembranes
![Page 3: Biomarkers and Risk Assessment for Chromium(VI) Qingshan Qu, MD (PI) Roy Shore, PhD (Co-I) Dept. of Environmental Med. NYU School of Medicine](https://reader036.vdocuments.mx/reader036/viewer/2022081519/56649d2a5503460f949fede7/html5/thumbnails/3.jpg)
Public Health RisksPublic Health Risks
Cr(VI) is public health concern: Cr(VI) is public health concern: Superfund site contaminantSuperfund site contaminant
Current Risk Assessments based Current Risk Assessments based on extrapolations: high-to-low on extrapolations: high-to-low concentrations and/or animal-to-concentrations and/or animal-to-humanhuman
![Page 4: Biomarkers and Risk Assessment for Chromium(VI) Qingshan Qu, MD (PI) Roy Shore, PhD (Co-I) Dept. of Environmental Med. NYU School of Medicine](https://reader036.vdocuments.mx/reader036/viewer/2022081519/56649d2a5503460f949fede7/html5/thumbnails/4.jpg)
Study ApproachStudy Approach
Measure exposure levels, internal Measure exposure levels, internal dose, markers for biologically dose, markers for biologically effective dose & genotoxicity.effective dose & genotoxicity.
Ultimate goal: determine which Ultimate goal: determine which biomarkers are useful quantitative biomarkers are useful quantitative indicators of Cr(VI) exposure at low indicators of Cr(VI) exposure at low levels for future epidemiology or levels for future epidemiology or surveillancesurveillance
![Page 5: Biomarkers and Risk Assessment for Chromium(VI) Qingshan Qu, MD (PI) Roy Shore, PhD (Co-I) Dept. of Environmental Med. NYU School of Medicine](https://reader036.vdocuments.mx/reader036/viewer/2022081519/56649d2a5503460f949fede7/html5/thumbnails/5.jpg)
Intermediate Objectives for Intermediate Objectives for Biomarker Validation & UtilityBiomarker Validation & UtilityExamine the reproducibility of each Examine the reproducibility of each biomarker (intraindividual vs. biomarker (intraindividual vs. interindividual variability)interindividual variability)
Measure sensitivity of biomarker at Measure sensitivity of biomarker at progressively lower levelsprogressively lower levels
Examine the specificity of the biomarker Examine the specificity of the biomarker
(? affected by smoking, diet, age, other (? affected by smoking, diet, age, other metal exposures?)metal exposures?)
![Page 6: Biomarkers and Risk Assessment for Chromium(VI) Qingshan Qu, MD (PI) Roy Shore, PhD (Co-I) Dept. of Environmental Med. NYU School of Medicine](https://reader036.vdocuments.mx/reader036/viewer/2022081519/56649d2a5503460f949fede7/html5/thumbnails/6.jpg)
Exposure BiomarkersExposure Biomarkers
Plasma Cr – Cr(III), some Cr(VI)Plasma Cr – Cr(III), some Cr(VI)
Erythrocyte or Lymphocyte Cr – Erythrocyte or Lymphocyte Cr – source mainly Cr(VI) [but is reduced source mainly Cr(VI) [but is reduced to Cr(III) within the cell]to Cr(III) within the cell]
Dose-response may be affected by Dose-response may be affected by plasma reduction capacityplasma reduction capacity
![Page 7: Biomarkers and Risk Assessment for Chromium(VI) Qingshan Qu, MD (PI) Roy Shore, PhD (Co-I) Dept. of Environmental Med. NYU School of Medicine](https://reader036.vdocuments.mx/reader036/viewer/2022081519/56649d2a5503460f949fede7/html5/thumbnails/7.jpg)
Markers of Biological Effects or Markers of Biological Effects or SusceptibilitySusceptibility
DNA-protein cross-links (DPC) in leukocytes DNA-protein cross-links (DPC) in leukocytes (assess biologically effective dose?)(assess biologically effective dose?)
Comet assay – detects DNA single-strand Comet assay – detects DNA single-strand breaks or incomplete repair, alkali-labile breaks or incomplete repair, alkali-labile sites, DNA-DNA or DNA-protein cross-linkingsites, DNA-DNA or DNA-protein cross-linking
Susceptibility markers of extracellular Susceptibility markers of extracellular reduction capacityreduction capacity– Ratio of Cr in erythrocytes to that in plasmaRatio of Cr in erythrocytes to that in plasma– Plasma ascorbate levelsPlasma ascorbate levels– Plasma oxidative statusPlasma oxidative status
![Page 8: Biomarkers and Risk Assessment for Chromium(VI) Qingshan Qu, MD (PI) Roy Shore, PhD (Co-I) Dept. of Environmental Med. NYU School of Medicine](https://reader036.vdocuments.mx/reader036/viewer/2022081519/56649d2a5503460f949fede7/html5/thumbnails/8.jpg)
Methods & Procedures – I.Methods & Procedures – I.
Identified factories with Cr exposureIdentified factories with Cr exposure
Conducted walk-throughs to select Conducted walk-throughs to select factoriesfactories
Talked with management & then Talked with management & then employees about the studyemployees about the study
Administered questionnaire re: Administered questionnaire re: smoking, health status, etc. so as to smoking, health status, etc. so as to select subjectsselect subjects
![Page 9: Biomarkers and Risk Assessment for Chromium(VI) Qingshan Qu, MD (PI) Roy Shore, PhD (Co-I) Dept. of Environmental Med. NYU School of Medicine](https://reader036.vdocuments.mx/reader036/viewer/2022081519/56649d2a5503460f949fede7/html5/thumbnails/9.jpg)
Methods & Procedures – II.Methods & Procedures – II.
Physical examPhysical exam
Personal exposure monitoring – one 8 hr Personal exposure monitoring – one 8 hr shiftshift– Used personal monitor with pumpUsed personal monitor with pump
Urine sample at end of workday – for Urine sample at end of workday – for cotinine & creatininecotinine & creatinine
10 ml blood sample – separated into 10 ml blood sample – separated into plasma, lymphocytes & erythrocytesplasma, lymphocytes & erythrocytes
For 8 subjects monitored & blood on 3 For 8 subjects monitored & blood on 3 successive Mondayssuccessive Mondays
![Page 10: Biomarkers and Risk Assessment for Chromium(VI) Qingshan Qu, MD (PI) Roy Shore, PhD (Co-I) Dept. of Environmental Med. NYU School of Medicine](https://reader036.vdocuments.mx/reader036/viewer/2022081519/56649d2a5503460f949fede7/html5/thumbnails/10.jpg)
Methods & Procedures – III.Methods & Procedures – III.
In year 1, obtained 25 exposed & 25 In year 1, obtained 25 exposed & 25 unexposed (farmers >50 miles away)unexposed (farmers >50 miles away)
In year 2, just completed obtaining exposure In year 2, just completed obtaining exposure & bloods on another 125 exposed & 30 & bloods on another 125 exposed & 30 unexposedunexposed
Subjects in year 1 were mostly highly Subjects in year 1 were mostly highly exposed, those in year 2 have a broad range exposed, those in year 2 have a broad range of lower exposuresof lower exposures
Each year spent >1 mo. in China collecting Each year spent >1 mo. in China collecting datadata
![Page 11: Biomarkers and Risk Assessment for Chromium(VI) Qingshan Qu, MD (PI) Roy Shore, PhD (Co-I) Dept. of Environmental Med. NYU School of Medicine](https://reader036.vdocuments.mx/reader036/viewer/2022081519/56649d2a5503460f949fede7/html5/thumbnails/11.jpg)
Principal Statistical AnalysesPrincipal Statistical Analyses
Examine reproducibility of biomarkerExamine reproducibility of biomarker
Determine initial sensitivity of Determine initial sensitivity of biomarker assay to detect high-biomarker assay to detect high-exposure effectsexposure effects
Examine slope & shape of exposure-Examine slope & shape of exposure-response curveresponse curve
Evaluate sensitivity of biomarker at Evaluate sensitivity of biomarker at lower exposure levelslower exposure levels
![Page 12: Biomarkers and Risk Assessment for Chromium(VI) Qingshan Qu, MD (PI) Roy Shore, PhD (Co-I) Dept. of Environmental Med. NYU School of Medicine](https://reader036.vdocuments.mx/reader036/viewer/2022081519/56649d2a5503460f949fede7/html5/thumbnails/12.jpg)
Statistical Analyses – Other Statistical Analyses – Other ConsiderationsConsiderations
Control for possible confounding Control for possible confounding variables: age, sex, smokingvariables: age, sex, smoking
For Cr(VI), evaluate & adjust for For Cr(VI), evaluate & adjust for exposures to Cr(III) & to nickelexposures to Cr(III) & to nickel
Is Cr(VI) exposure-response relation Is Cr(VI) exposure-response relation modified by plasma reduction modified by plasma reduction capacity, serum vitamin C or capacity, serum vitamin C or oxidative status?oxidative status?
![Page 13: Biomarkers and Risk Assessment for Chromium(VI) Qingshan Qu, MD (PI) Roy Shore, PhD (Co-I) Dept. of Environmental Med. NYU School of Medicine](https://reader036.vdocuments.mx/reader036/viewer/2022081519/56649d2a5503460f949fede7/html5/thumbnails/13.jpg)
y = 2.1621x + 0.3563R = 0.6541P<0.0001
-0.5
0.0
0.5
1.0
1.5
2.0
0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7
Cr(VI) Exposure [Ln(1 + xmg/m 3)
Cr
in R
BC
[L
og
(xu
g/1
012 R
BC
)]
Fig. 1 Correlation between personal exposure and Cr levels in RBC
![Page 14: Biomarkers and Risk Assessment for Chromium(VI) Qingshan Qu, MD (PI) Roy Shore, PhD (Co-I) Dept. of Environmental Med. NYU School of Medicine](https://reader036.vdocuments.mx/reader036/viewer/2022081519/56649d2a5503460f949fede7/html5/thumbnails/14.jpg)
y = 105.81x + 27.955R = 0.5615P<0.0001
0
20
40
60
80
100
120
0.0 0.2 0.4 0.6 0.8
Cr(VI) Exposure [Ln(1+x mg/m 3)]
Sco
res
of
Co
met
Ass
ay
Fig. 3 Correlation between comet scores and personal exposure to Cr(VI)
![Page 15: Biomarkers and Risk Assessment for Chromium(VI) Qingshan Qu, MD (PI) Roy Shore, PhD (Co-I) Dept. of Environmental Med. NYU School of Medicine](https://reader036.vdocuments.mx/reader036/viewer/2022081519/56649d2a5503460f949fede7/html5/thumbnails/15.jpg)
y = 39.615x + 15.69R = 0.6951P<0.0001
-0.5 0.0 0.5 1.0 1.5 2.0
Cr in RBC [log(x ug/1012 RBC)]
Sco
res o
f C
om
et
Assay
Fig. 4 Correlation between comet scores and Cr levels in RBC
20
40
60
80
100
0
![Page 16: Biomarkers and Risk Assessment for Chromium(VI) Qingshan Qu, MD (PI) Roy Shore, PhD (Co-I) Dept. of Environmental Med. NYU School of Medicine](https://reader036.vdocuments.mx/reader036/viewer/2022081519/56649d2a5503460f949fede7/html5/thumbnails/16.jpg)
y = 1.5366x + 1.4265R = 0.8085P<0.0001
-0.5 0.0 0.5 1.0 1.5 2.0
Cr in RBC [log(x ug/1012 RBC)]
8-O
Hd
G [
log
(x u
g/g
cre
ati
nin
e)]
Fig. 6 Correlation between urinary 8-OHdG and Cr levels in RBC
0
1
2
3
4
![Page 17: Biomarkers and Risk Assessment for Chromium(VI) Qingshan Qu, MD (PI) Roy Shore, PhD (Co-I) Dept. of Environmental Med. NYU School of Medicine](https://reader036.vdocuments.mx/reader036/viewer/2022081519/56649d2a5503460f949fede7/html5/thumbnails/17.jpg)
Biomarkers and Risk Biomarkers and Risk Assessment for Assessment for Chromium(VI)Chromium(VI)
Qingshan Qu, MD (PI)Qingshan Qu, MD (PI)[email protected]@env.med.nyu.eduDept. of Environmental Med.Dept. of Environmental Med.
NYU School of MedicineNYU School of Medicine